Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Farmers Insurance
Chubb
Argus Health
McKesson
UBS
Fuji
Cipla
US Army

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NPH PURIFIED PORK ISOPHANE INSULIN

« Back to Dashboard

Clinical Trials for Nph Purified Pork Isophane Insulin

Trial ID Title Status Sponsor Phase Summary
NCT00658099 Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard® Completed Novo Nordisk A/S N/A This trial is conducted in Europe. The aim of this observational study is to evaluate the change in weight in type 2 diabetes patients using Levemir® or Insulatard® under normal clinical practice conditions.
NCT00665808 Observational Study on Treatment Satisfaction of Levemir® Versus Protaphane® During "Real-life" Usage in Germany Completed Novo Nordisk A/S N/A This NON INTERVENTIONAL OBSERVATIONAL STUDY is conducted in Europe. The purpose of this NON INTERVENTIONAL OBSERVATIONAL STUDY is to primarily investigate treatment satisfaction when using Levemir® versus Protaphane® in combination with OADs in daily settings.
NCT01122979 Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure. Completed Sanofi Phase 4 Primary Objective: >To obtain an estimation for both treatment groups of the proportion of patients that reach the target of HbA1c <= 7% without confirmed nocturnal hypoglycaemia in each treatment group. Secondary Objectives: - Glycemic control, measured by HbA1c and FPG (fasting plasma glucose) at baseline and after each period of treatment. - Incidence of confirmed symptomatic and nocturnal hypoglycemia. - Incidence of confirmed severe hypoglycemia (< 36mg/dL or need of help to recover). >Weight variation for each period of treatment. - Creatinine clearance at baseline and after each period of treatment. - Overall safety: Incidence of adverse events.
NCT01680185 Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation Active, not recruiting Medical University of Vienna Phase 3 The SAPT-NODAT study will test the hypotheses that intensive subcutaneous insulin treatment with short acting insulin, applied continuously through an insulin pump, (i) improves glycemic control, (ii) reduces the prevalence of NODAT and prediabetes, and (iii) offers further β-cell protection, in comparison to the standard of care control group, and the basal insulin treatment group. In the SAPT-NODAT study, we will employ sensor-augmented insulin-pump technology, which performs like a semi-closed loop to prevent hypoglycemic events. Patients in the SAPT-NODAT study will be followed through 24 months post-transplantation.
NCT01854723 Comparison Study of Insulin Glargine and NPH Insulin Enrolling by invitation Providence Health & Services Phase 4 This study will compare the safety, effectiveness, and cost of two different types of long-acting insulin.
NCT01963728 Comparison of Insulin Therapy in Treating Post-Transplant Diabetes Terminated Inova Health Care Services Phase 4 To determine if the use of insulin isophane results in improved control of blood sugars compared to the use of insulin glargine in new onset diabetes after kidney, lung, or heart transplantation (NODAT).
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Nph Purified Pork Isophane Insulin

Condition Name

Condition Name for Nph Purified Pork Isophane Insulin
Intervention Trials
Diabetes Mellitus, Type 2 3
Diabetes Mellitus 3
Diabetes 3
Hyperglycemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Nph Purified Pork Isophane Insulin
Intervention Trials
Diabetes Mellitus 6
Diabetes Mellitus, Type 2 3
Hyperglycemia 2
Renal Insufficiency 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Nph Purified Pork Isophane Insulin

Trials by Country

Trials by Country for Nph Purified Pork Isophane Insulin
Location Trials
Germany 3
United States 2
Romania 1
Austria 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Nph Purified Pork Isophane Insulin
Location Trials
Virginia 1
Oregon 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Nph Purified Pork Isophane Insulin

Clinical Trial Phase

Clinical Trial Phase for Nph Purified Pork Isophane Insulin
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 1 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Nph Purified Pork Isophane Insulin
Clinical Trial Phase Trials
Completed 5
Recruiting 1
Active, not recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Nph Purified Pork Isophane Insulin

Sponsor Name

Sponsor Name for Nph Purified Pork Isophane Insulin
Sponsor Trials
Medical University of Vienna 2
Novo Nordisk A/S 2
Julphar Gulf Pharmaceutical Industries 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Nph Purified Pork Isophane Insulin
Sponsor Trials
Other 7
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Dow
AstraZeneca
Johnson and Johnson
Chubb
McKesson
Julphar
Queensland Health
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.